Literature DB >> 8373715

Disposition of the enantiomers of hydroxychloroquine in patients with rheumatoid arthritis following multiple doses of the racemate.

A J McLachlan1, S E Tett, D J Cutler, R O Day.   

Abstract

In eight patients with rheumatoid arthritis receiving racemic hydroxychloroquine, blood and urine concentrations of the enantiomers of hydroxychloroquine and its major metabolites were measured each month over the first 6 months of therapy. Plasma concentrations of hydroxychloroquine enantiomers were measured in five of these patients. In all patients, the blood concentration of (R)-hydroxychloroquine exceeded that of the (S)-enantiomer, the mean (R)/(S) ratio being 2.2 (range 1.6-2.9). A similar excess of (R)-hydroxychloroquine was found in the plasma, the mean (R)/(S) ratio being 1.6 (range 1.2-1.9). The mean enantiomer blood concentration ratio (R)/(S) for the metabolite desethylhydroxychloroquine was 0.45 (range 0.34-0.58) and for desethylchloroquine it was 0.56 (range 0.35-0.86) suggesting stereoselective metabolism of hydroxychloroquine. (S)-hydroxychloroquine had a mean (+/- s.d.) renal clearance from blood of 41 +/- 11 ml min-1, approximately twice that of (R)-hydroxychloroquine. The predicted unbound renal clearance was also higher for (S)-hydroxychloroquine. The clinical implications of enantioselective disposition of hydroxychloroquine are currently not known.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8373715      PMCID: PMC1364560          DOI: 10.1111/j.1365-2125.1993.tb05897.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  7 in total

1.  High-performance liquid chromatographic separation of the enantiomers of hydroxychloroquine and its major metabolites in biological fluids using an alpha 1-acid glycoprotein stationary phase.

Authors:  A J McLachlan; S E Tett; D J Cutler
Journal:  J Chromatogr       Date:  1991-09-18

2.  Enantioselective analysis of chloroquine and desethylchloroquine after oral administration of racemic chloroquine.

Authors:  D Ofori-Adjei; O Ericsson; B Lindström; J Hermansson; K Adjepon-Yamoah; F Sjöqvist
Journal:  Ther Drug Monit       Date:  1986       Impact factor: 3.681

3.  High-performance liquid chromatographic assay for hydroxychloroquine and metabolites in blood and plasma, using a stationary phase of poly(styrene divinylbenzene) and a mobile phase at pH 11, with fluorimetric detection.

Authors:  S E Tett; D J Cutler; K F Brown
Journal:  J Chromatogr       Date:  1985-11-08

4.  A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers.

Authors:  S E Tett; D J Cutler; R O Day; K F Brown
Journal:  Br J Clin Pharmacol       Date:  1988-09       Impact factor: 4.335

5.  [Chloroquine enantiomers. Activity against P. vinckei and binding on DNA (author's transl)].

Authors:  E Fink; G Minet; P Nickel
Journal:  Arzneimittelforschung       Date:  1979

6.  Bioavailability of hydroxychloroquine tablets in healthy volunteers.

Authors:  S E Tett; D J Cutler; R O Day; K F Brown
Journal:  Br J Clin Pharmacol       Date:  1989-06       Impact factor: 4.335

7.  Antimalarial activity of the optical isomers of chloroquine diphosphate.

Authors:  A Haberkorn; H P Kraft; G Blaschke
Journal:  Tropenmed Parasitol       Date:  1979-09
  7 in total
  13 in total

Review 1.  Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements.

Authors:  J Ducharme; R Farinotti
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

Review 2.  Repurposing Drugs for COVID-19: Pharmacokinetics and Pharmacogenomics of Chloroquine and Hydroxychloroquine.

Authors:  Mariana Babayeva; Zvi Loewy
Journal:  Pharmgenomics Pers Med       Date:  2020-10-23

3.  Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax.

Authors:  Hyeong-Seok Lim; Jeong-Soo Im; Joo-Youn Cho; Kyun-Seop Bae; Terry A Klein; Joon-Sup Yeom; Tae-Seon Kim; Jae-Seon Choi; In-Jin Jang; Jae-Won Park
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

Review 4.  Stereoselectivity in the pharmacodynamics and pharmacokinetics of the chiral antimalarial drugs.

Authors:  Dion R Brocks; Reza Mehvar
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

5.  Enantioselective disposition of hydroxychloroquine after a single oral dose of the racemate to healthy subjects.

Authors:  J Ducharme; H Fieger; M P Ducharme; S K Khalil; I W Wainer
Journal:  Br J Clin Pharmacol       Date:  1995-08       Impact factor: 4.335

Review 6.  Clinical pharmacokinetics of slow-acting antirheumatic drugs.

Authors:  S E Tett
Journal:  Clin Pharmacokinet       Date:  1993-11       Impact factor: 6.447

7.  Development of a Physiologically Based Pharmacokinetic Model for Hydroxychloroquine and Its Application in Dose Optimization in Specific COVID-19 Patients.

Authors:  Miao Zhang; Xueting Yao; Zhe Hou; Xuan Guo; Siqi Tu; Zihan Lei; Zhiheng Yu; Xuanlin Liu; Cheng Cui; Xijing Chen; Ning Shen; Chunli Song; Jie Qiao; Xiaoqiang Xiang; Haiyan Li; Dongyang Liu
Journal:  Front Pharmacol       Date:  2021-02-12       Impact factor: 5.810

Review 8.  Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.

Authors:  K D Rainsford; Ann L Parke; Matthew Clifford-Rashotte; W F Kean
Journal:  Inflammopharmacology       Date:  2015-08-06       Impact factor: 5.093

9.  Recent Clinical and Preclinical Studies of Hydroxychloroquine on RNA Viruses and Chronic Diseases: A Systematic Review.

Authors:  Immacolata Faraone; Fabiana Labanca; Maria Ponticelli; Nunziatina De Tommasi; Luigi Milella
Journal:  Molecules       Date:  2020-11-14       Impact factor: 4.411

Review 10.  Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection.

Authors:  Melanie R Nicol; Abhay Joshi; Matthew L Rizk; Philip E Sabato; Radojka M Savic; David Wesche; Jenny H Zheng; Jack Cook
Journal:  Clin Pharmacol Ther       Date:  2020-09-01       Impact factor: 6.903

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.